This first-reported association between such crystals and EZH2/DNMT3A-mutated AML highlights their potential as high-risk markers. The findings implicate epigenetic dysregulation in treatment resistance and thrombogenesis, warranting cryo-EM studies to elucidate crystal composition and mechanisms. Clinically, this supports vigilant thromboprophylaxis and exploration of combined epigenetic/anticoagulant therapies for similar high-risk cases.
Liu et al. (Thu,) studied this question.